11C-Acetate PET/CT Imaging As a Biomarker of Amyloid-Induced Neuroinflammation

Inclusion Criteria

• •1. Participants will be at least 65 years of age
• •2. Positive brain amyloid PET/CT scan within 6 months of study screening
• •3. Mini-mental status examination (MMSE) score ≥ 24 at screening visit
• •4. A brain MRI is required. If a brain MRI has been performed within 6 months of 11C-Acetate PET/CT and of adequate quality that scan may be used for the study analysis, subjects who do not have a brain MRI will undergo a brain MRI as a part of this study
• •5. Participants must identify a study partner who is willing to accompany the patient to study visits
• •6. Participants must be informed of the investigational nature of this study and provide written informed consent in accordance with institutional and federal guidelines prior to study-specific procedures. If the patient is unable to provide informed consent, the patient's legal representative may consent on behalf of the patient but the patient will be asked to confirm assent.
• •1. Participants will be at least 65 years of age
• •2. History of negative brain amyloid PET/CT scan within 6 months of study screening OR negative cerebrospinal fluid (CSF) analysis for AD biomarkers within 6 months of study screening
• •3. Mini-mental status examination (MMSE) \> 27 at screening visit
• •4. A brain MRI is required. If a brain MRI has been performed within 6 months of enrollment to this study and of adequate quality that scan may be used for the study analysis, subjects who do not have a brain MRI will undergo a brain MRI as a part of this study
• •5. Participants must be informed of the investigational nature of this study and provide written informed consent in accordance with institutional and federal guidelines prior to study-specific procedures.